ASTRANA HEALTH INC (ASTH) Stock Fundamental Analysis

NASDAQ:ASTH • US03763A2078

26.32 USD
+5.99 (+29.46%)
At close: Mar 2, 2026
27.7 USD
+1.38 (+5.24%)
After Hours: 3/2/2026, 8:02:57 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

4

Taking everything into account, ASTH scores 4 out of 10 in our fundamental rating. ASTH was compared to 101 industry peers in the Health Care Providers & Services industry. ASTH has a medium profitability rating, but doesn't score so well on its financial health evaluation. ASTH is not overvalued while it is showing excellent growth. This is an interesting combination.


Dividend Valuation Growth Profitability Health

4

1. Profitability

1.1 Basic Checks

  • ASTH had positive earnings in the past year.
  • In the past year ASTH had a positive cash flow from operations.
  • ASTH had positive earnings in each of the past 5 years.
  • Each year in the past 5 years ASTH had a positive operating cash flow.
ASTH Yearly Net Income VS EBIT VS OCF VS FCFASTH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

1.2 Ratios

  • ASTH's Return On Assets of 0.43% is in line compared to the rest of the industry. ASTH outperforms 49.51% of its industry peers.
  • ASTH has a Return On Equity of 1.23%. This is comparable to the rest of the industry: ASTH outperforms 55.45% of its industry peers.
  • The Return On Invested Capital of ASTH (2.95%) is comparable to the rest of the industry.
  • Measured over the past 3 years, the Average Return On Invested Capital for ASTH is below the industry average of 9.12%.
  • The 3 year average ROIC (7.07%) for ASTH is well above the current ROIC(2.95%). The reason for the recent decline needs to be investigated.
Industry RankSector Rank
ROA 0.43%
ROE 1.23%
ROIC 2.95%
ROA(3y)4.79%
ROA(5y)5.42%
ROE(3y)8.09%
ROE(5y)10.17%
ROIC(3y)7.07%
ROIC(5y)7.37%
ASTH Yearly ROA, ROE, ROICASTH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 5 10 15

1.3 Margins

  • ASTH has a Profit Margin (0.33%) which is comparable to the rest of the industry.
  • ASTH's Profit Margin has declined in the last couple of years.
  • ASTH has a Operating Margin (2.59%) which is comparable to the rest of the industry.
  • In the last couple of years the Operating Margin of ASTH has declined.
  • Looking at the Gross Margin, with a value of 10.25%, ASTH is doing worse than 73.27% of the companies in the same industry.
  • In the last couple of years the Gross Margin of ASTH has declined.
Industry RankSector Rank
OM 2.59%
PM (TTM) 0.33%
GM 10.25%
OM growth 3Y-29.78%
OM growth 5YN/A
PM growth 3Y-38.02%
PM growth 5YN/A
GM growth 3Y-16.57%
GM growth 5YN/A
ASTH Yearly Profit, Operating, Gross MarginsASTH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 5 10 15 20

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so ASTH is destroying value.
  • ASTH has more shares outstanding than it did 1 year ago.
  • Compared to 1 year ago, ASTH has a worse debt to assets ratio.
ASTH Yearly Shares OutstandingASTH Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 10M 20M 30M 40M
ASTH Yearly Total Debt VS Total AssetsASTH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

  • ASTH has an Altman-Z score of 2.15. This is not the best score and indicates that ASTH is in the grey zone with still only limited risk for bankruptcy at the moment.
  • ASTH has a Altman-Z score (2.15) which is in line with its industry peers.
  • The Debt to FCF ratio of ASTH is 10.83, which is on the high side as it means it would take ASTH, 10.83 years of fcf income to pay off all of its debts.
  • ASTH has a Debt to FCF ratio of 10.83. This is comparable to the rest of the industry: ASTH outperforms 44.55% of its industry peers.
  • A Debt/Equity ratio of 1.29 is on the high side and indicates that ASTH has dependencies on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 1.29, ASTH is doing worse than 65.35% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 1.29
Debt/FCF 10.83
Altman-Z 2.15
ROIC/WACC0.37
WACC8.02%
ASTH Yearly LT Debt VS Equity VS FCFASTH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 200M 400M 600M

2.3 Liquidity

  • A Current Ratio of 1.40 indicates that ASTH should not have too much problems paying its short term obligations.
  • ASTH has a Current ratio (1.40) which is comparable to the rest of the industry.
  • A Quick Ratio of 1.40 indicates that ASTH should not have too much problems paying its short term obligations.
  • ASTH has a Quick ratio of 1.40. This is comparable to the rest of the industry: ASTH outperforms 59.41% of its industry peers.
Industry RankSector Rank
Current Ratio 1.4
Quick Ratio 1.4
ASTH Yearly Current Assets VS Current LiabilitesASTH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

8

3. Growth

3.1 Past

  • The earnings per share for ASTH have decreased strongly by -85.38% in the last year.
  • Measured over the past years, ASTH shows a quite strong growth in Earnings Per Share. The EPS has been growing by 19.19% on average per year.
  • ASTH shows a strong growth in Revenue. In the last year, the Revenue has grown by 68.17%.
  • Measured over the past years, ASTH shows a very strong growth in Revenue. The Revenue has been growing by 38.01% on average per year.
EPS 1Y (TTM)-85.38%
EPS 3Y-17.24%
EPS 5Y19.19%
EPS Q2Q%-96.97%
Revenue 1Y (TTM)68.17%
Revenue growth 3Y38.01%
Revenue growth 5YN/A
Sales Q2Q%99.71%

3.2 Future

  • The Earnings Per Share is expected to grow by 31.87% on average over the next years. This is a very strong growth
  • ASTH is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 18.29% yearly.
EPS Next Y-43.43%
EPS Next 2Y19.69%
EPS Next 3Y29.02%
EPS Next 5Y31.87%
Revenue Next Year59.13%
Revenue Next 2Y41.16%
Revenue Next 3Y30.2%
Revenue Next 5Y18.29%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
ASTH Yearly Revenue VS EstimatesASTH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 1B 2B 3B 4B 5B
ASTH Yearly EPS VS EstimatesASTH Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 1 2 3 4

More info and screens

Find the best growth stocksShow best growing peers

4

4. Valuation

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 138.53, the valuation of ASTH can be described as expensive.
  • Compared to the rest of the industry, the Price/Earnings ratio of ASTH is on the same level as its industry peers.
  • Compared to an average S&P500 Price/Earnings ratio of 27.13, ASTH is valued quite expensively.
  • With a Price/Forward Earnings ratio of 20.64, ASTH is valued on the expensive side.
  • ASTH's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. ASTH is cheaper than 76.24% of the companies in the same industry.
  • ASTH is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 28.11, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 138.53
Fwd PE 20.64
ASTH Price Earnings VS Forward Price EarningsASTH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80 100

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of ASTH is on the same level as its industry peers.
  • Based on the Price/Free Cash Flow ratio, ASTH is valued cheaper than 82.18% of the companies in the same industry.
Industry RankSector Rank
P/FCF 13.62
EV/EBITDA 14.25
ASTH Per share dataASTH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 40

4.3 Compensation for Growth

  • ASTH's earnings are expected to grow with 29.02% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)7.22
EPS Next 2Y19.69%
EPS Next 3Y29.02%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • ASTH does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ASTRANA HEALTH INC

NASDAQ:ASTH (3/2/2026, 8:02:57 PM)

After market: 27.7 +1.38 (+5.24%)

26.32

+5.99 (+29.46%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)11-06
Earnings (Next)03-02
Inst Owners55.03%
Inst Owner ChangeN/A
Ins Owners9.86%
Ins Owner Change0.95%
Market Cap1.32B
Revenue(TTM)2.90B
Net Income(TTM)9.54M
Analysts84.71
Price Target36.38 (38.22%)
Short Float %6.57%
Short Ratio4.62
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend0.09
Dividend Growth(5Y)N/A
DP86.52%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-73.24%
Min EPS beat(2)-97.78%
Max EPS beat(2)-48.7%
EPS beat(4)0
Avg EPS beat(4)-104%
Min EPS beat(4)-225.16%
Max EPS beat(4)-44.39%
EPS beat(8)4
Avg EPS beat(8)-42.64%
EPS beat(12)7
Avg EPS beat(12)-21.5%
EPS beat(16)10
Avg EPS beat(16)-9.93%
Revenue beat(2)1
Avg Revenue beat(2)-0.53%
Min Revenue beat(2)-1.62%
Max Revenue beat(2)0.57%
Revenue beat(4)2
Avg Revenue beat(4)0.26%
Min Revenue beat(4)-3.56%
Max Revenue beat(4)5.66%
Revenue beat(8)5
Avg Revenue beat(8)0.99%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-3.31%
PT rev (3m)-15.83%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-56.73%
EPS NY rev (1m)0%
EPS NY rev (3m)-58.79%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.69%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.5%
Valuation
Industry RankSector Rank
PE 138.53
Fwd PE 20.64
P/S 0.46
P/FCF 13.62
P/OCF 12.39
P/B 1.7
P/tB N/A
EV/EBITDA 14.25
EPS(TTM)0.19
EY0.72%
EPS(NY)1.27
Fwd EY4.84%
FCF(TTM)1.93
FCFY7.34%
OCF(TTM)2.12
OCFY8.07%
SpS57.74
BVpS15.46
TBVpS-7.43
PEG (NY)N/A
PEG (5Y)7.22
Graham Number8.13
Profitability
Industry RankSector Rank
ROA 0.43%
ROE 1.23%
ROCE 4.68%
ROIC 2.95%
ROICexc 4.15%
ROICexgc N/A
OM 2.59%
PM (TTM) 0.33%
GM 10.25%
FCFM 3.35%
ROA(3y)4.79%
ROA(5y)5.42%
ROE(3y)8.09%
ROE(5y)10.17%
ROIC(3y)7.07%
ROIC(5y)7.37%
ROICexc(3y)11.13%
ROICexc(5y)11.73%
ROICexgc(3y)50.18%
ROICexgc(5y)49.73%
ROCE(3y)11.21%
ROCE(5y)11.68%
ROICexgc growth 3Y-13.47%
ROICexgc growth 5YN/A
ROICexc growth 3Y-16.27%
ROICexc growth 5YN/A
OM growth 3Y-29.78%
OM growth 5YN/A
PM growth 3Y-38.02%
PM growth 5YN/A
GM growth 3Y-16.57%
GM growth 5YN/A
F-Score3
Asset Turnover1.29
Health
Industry RankSector Rank
Debt/Equity 1.29
Debt/FCF 10.83
Debt/EBITDA 8.9
Cap/Depr 25.55%
Cap/Sales 0.33%
Interest Coverage 2.01
Cash Conversion 94.59%
Profit Quality 1016.69%
Current Ratio 1.4
Quick Ratio 1.4
Altman-Z 2.15
F-Score3
WACC8.02%
ROIC/WACC0.37
Cap/Depr(3y)106.76%
Cap/Depr(5y)87.27%
Cap/Sales(3y)1.49%
Cap/Sales(5y)1.42%
Profit Quality(3y)99.59%
Profit Quality(5y)98.35%
High Growth Momentum
Growth
EPS 1Y (TTM)-85.38%
EPS 3Y-17.24%
EPS 5Y19.19%
EPS Q2Q%-96.97%
EPS Next Y-43.43%
EPS Next 2Y19.69%
EPS Next 3Y29.02%
EPS Next 5Y31.87%
Revenue 1Y (TTM)68.17%
Revenue growth 3Y38.01%
Revenue growth 5YN/A
Sales Q2Q%99.71%
Revenue Next Year59.13%
Revenue Next 2Y41.16%
Revenue Next 3Y30.2%
Revenue Next 5Y18.29%
EBIT growth 1Y-11.33%
EBIT growth 3Y-3.09%
EBIT growth 5YN/A
EBIT Next Year101.88%
EBIT Next 3Y44.42%
EBIT Next 5Y30.45%
FCF growth 1Y11.26%
FCF growth 3Y-4.75%
FCF growth 5YN/A
OCF growth 1Y-23.49%
OCF growth 3Y-9.46%
OCF growth 5YN/A

ASTRANA HEALTH INC / ASTH FAQ

Can you provide the ChartMill fundamental rating for ASTRANA HEALTH INC?

ChartMill assigns a fundamental rating of 4 / 10 to ASTH.


What is the valuation status of ASTRANA HEALTH INC (ASTH) stock?

ChartMill assigns a valuation rating of 4 / 10 to ASTRANA HEALTH INC (ASTH). This can be considered as Fairly Valued.


How profitable is ASTRANA HEALTH INC (ASTH) stock?

ASTRANA HEALTH INC (ASTH) has a profitability rating of 4 / 10.


What is the valuation of ASTRANA HEALTH INC based on its PE and PB ratios?

The Price/Earnings (PE) ratio for ASTRANA HEALTH INC (ASTH) is 138.53 and the Price/Book (PB) ratio is 1.7.


Can you provide the financial health for ASTH stock?

The financial health rating of ASTRANA HEALTH INC (ASTH) is 3 / 10.